Dibenzo-alpha chromoproteins

Dibenzo-alpha-Pyrone Chromoproteins (DCPs): A Reference Article

Overview and Critical Identification Note

"Dibenzo-alpha chromoproteins" — more precisely termed dibenzo-alpha-pyrone chromoproteins (abbreviated DCPs) — do not exist in the scientific, regulatory, or pharmacopeial literature as an isolated, standalone dietary supplement ingredient. A thorough search of PubMed/PMC, U.S. and international patent databases, and regulatory databases finds no authoritative source describing "dibenzo-alpha chromoproteins" as an independent supplement with its own identity, chemical characterization, traditional use history, or clinical evidence base separate from its source material.

Every peer-reviewed study, patent document, and government-adjacent reference that uses any form of this term does so exclusively in the context of shilajit (also spelled shilajatu, salajeet, or mumie/mumijo), describing DCPs as one quantifiable bioactive fraction within that complex natural exudate. DCPs are described in patent literature as a composition of oxygenated dibenzo-alpha-pyrone or its conjugates, phosphocreatine, proteins, fatty acyl esters of glycerol, and other small ligands such as carotenoids, sterols, and aromatic acids, isolated from shilajit, fossils of ammonites, corals, and other invertebrates. These findings establish DCPs as the major bioactives of shilajit.

One commercial database (DigiComply) contains an entry for "dibenzo-alpha chromoproteins" as a standalone supplement, but that entry explicitly states it is automatically generated by an AI system, may not contain verified information, and should not be used as an authoritative source. All factual content in this article is therefore drawn exclusively from peer-reviewed research and patent documents pertaining to DCPs within shilajit.

Identity and Chemical Characterization

Nomenclature

The full and scientifically precise name is dibenzo-alpha-pyrone chromoproteins, abbreviated as DCPs. The parent chemical class is dibenzo-alpha-pyrones (DBPs) — hydroxylated lactone compounds. In native shilajit, DBPs appear in three forms: free-floating molecules, complexes nested within humic acids, and bound to proteins as dibenzo-alpha-pyrone chromoproteins (DCPs). The core DBPs chemically conjugate with lipids, chromopeptides, and natural pigments to form DCPs, which are highly stable, pigmented organo-mineral complexes.

Primary Bioactive Compounds Within DCPs

The two primary bioactive markers are 3-hydroxydibenzo-alpha-pyrone, known as Urolithin B, and 3,8-dihydroxydibenzo-alpha-pyrone, known as Urolithin A. Hydroxylated dibenzo-alpha-pyrones (DBPs) and their acyl and aminoacyl derivatives are the key bioactive components of shilajit. DBPs (and equivalents) are endogenously synthesized from PUFAs (EPA/DHA) and also occur in animal mitochondria and blood.

Natural Source and Formation

Shilajit is a pale-brown to blackish-brown exudate that oozes from sedimentary rocks worldwide, largely in the Himalayas. It is a complex, sticky exudate found primarily in the rocks of the Himalayas, formed over centuries by the slow decomposition of specific plants by the action of microorganisms, and in its raw form is a highly variable mixture of organic and inorganic compounds. The DBPs in authentic Himalayan shilajit are the result of centuries-long biotransformation by rock-dwelling fungi, not a quick extraction from soil. DCPs are additionally isolable from fossils of ammonites, corals, and other marine invertebrates, as described in U.S. Patent Application No. 20050233942 and Canadian Patent Application CA2562829.

Shilajit is known by a range of names across cultures and languages: silajatu (Bengali), mummio or mumie (Russian), hajar-ul-musa (Arabic), asphalt or mineral pitch (English), and asphaltum (Latin/botanical nomenclature).

Analytical Quantification

In standardized commercial preparations, DCPs are quantified by high-performance liquid chromatography (HPLC). A clinically studied preparation (PrimaVie™) was standardized to contain not less than 60% w/w of total bioactives, including not less than 50% w/w of fulvic acids (FAs), not less than 0.3% w/w of dibenzo-alpha-pyrones (DBPs), and not less than 10% w/w of dibenzo-alpha-pyrone chromoproteins (DCPs), as quantified by HPLC using external standards isolated from shilajit extract by low-pressure chromatography. On the HPLC chromatogram, dibenzochromoproteins (DCPs) elute at retention time 3.0–5.8 min; 3,8-(OH)₂-dibenzo-alpha-pyrone at 9.07 min; and 3-OH-dibenzo-alpha-pyrone at 26.02 min.

In at least one preclinical study, processed shilajit was standardized to DBPs at 0.43% w/w, DCP-chromoproteins at 20.45% w/w, and fulvic acids at 56.75% w/w.

Traditional and Historical Use

Ayurvedic Tradition (India)

Shilajit is mentioned under the rasayana category in the Charaka Samhita, the oldest text of the Ayurvedic system of medicine. Charaka stated that shilajit can be used in several diseases by altering the anupana (vehicle) and adjuvant in combination with several drugs. The Sushruta Samhita describes shilajit in the context of madhumeha chikitsa (the treatment of diabetes mellitus), where purified shilajit is advocated alongside the decoction of Shorea robusta group plants.

The Charaka Samhita dates to approximately the first or second century CE, while the Sushruta Samhita was likely compiled around the sixth century CE. Both texts describe shilajit as a powerful rasayana, a category of substances believed to promote longevity, vitality, and rejuvenation.

Shilajit's history can be traced back over 3,000 years, making it one of the oldest known substances in Ayurveda. The term "shilajit" is derived from the Sanskrit words "shila" meaning rock and "jit" meaning conquered, reflecting its origin as a resinous substance that oozes from the cracks and crevices of rocks in the Himalayan and Altai Mountain ranges.

Over centuries, the preparation evolved from raw shilajit lumps to powdered forms, then to ghrita (ghee-based) and arka (distillate) preparations. By early medieval times, Ayurvedic alchemists combined shilajit with herbal bhasmas (calcined metal oxides) to potentiate its effects for rheumatoid complaints and male virility.

In Ayurveda, shilajit was primarily used as a rasayana, a category of substances believed to promote longevity, prevent aging, and enhance overall vitality. Rasayana therapy was considered one of the eight branches of Ayurveda, highlighting its importance in traditional medicine.

Traditional Ayurvedic texts provide specific guidelines for shilajit dosage and administration. The typical dose ranged from one to three "ratti" (approximately 125–375 mg in modern measurements), taken with various anupanas (vehicles) depending on the condition being treated.

Classification in Classical Texts

Shilajit is categorized in classical Ayurvedic texts based on mineral content and origin: Suvarna (Gold Shilajit), beneficial for Vata and Pitta imbalance; Rajata (Silver Shilajit), used for specific doshic imbalances and rejuvenation; Tamra (Copper Shilajit), supporting metabolic strength; and Krishna Lauh (Black Iron Shilajit), considered most potent and supporting all-around wellness.

Traditional Use in Other Cultures

Ancient peoples across Nepal, Tibet, Pakistan, and China also used shilajit independently, and Greek philosopher Aristotle may have known about it, suggesting its reputation spread across cultures even in ancient times. Ibn Sina, also known as Avicenna, was an 11th-century Persian physician and philosopher who described shilajit in his Canon of Medicine as a versatile remedy used by folk healers across the Islamic world, documenting its application for conditions including colds, bone dislocations, and hearing loss.

In Tibet, shilajit was known as "brag-zhun" and used in traditional Tibetan medicine for similar rejuvenative purposes.

By the 16th century CE, Raja Nighantu texts introduced standardized weight-based dosing. By the 19th century, colonial-era practitioners documented shilajit for treating tuberculosis and chronic fevers.

Key Constituents and Active Compounds

DCPs are one fraction within the broader chemical complexity of shilajit. Shilajit is endowed with anti-stress, memory- and energy-enhancing, antioxidant, anti-inflammatory, antidiabetic, spermatogenic, neuroprotective, antiulcer, and wound-healing activities. These pharmacological effects are mainly attributed to the presence of humic acid, fulvic acid, dibenzo-alpha-pyrones, dibenzo-alpha-pyrone chromoproteins, and trace elements.

The DCP structural composition, as described in patent literature, includes:

• Oxygenated dibenzo-alpha-pyrone or its conjugates, phosphocreatine, proteins, fatty acyl esters of glycerol, and other small ligands including carotenoids, sterols, and aromatic acids as core structural fragments.
• 3-hydroxydibenzo-alpha-pyrone (3-OH-DBP; equivalent to Urolithin B)
• 3,8-dihydroxydibenzo-alpha-pyrone (3,8-(OH)₂-DBP; equivalent to Urolithin A)

A 2012 peer-reviewed paper published in the International Journal of Alzheimer's Disease provides a compositional overview of shilajit as a natural phytocomplex, detailing its composition of fulvic acid, dibenzo-alpha-pyrones, and humic substances, and its formation from the gradual decomposition of plant species including Euphorbia royleana and Trifolium repens.

Mechanisms of Action

Mitochondrial Electron Transport Chain Activity

The most extensively characterized proposed mechanism for DCPs and their parent DBPs centers on the mitochondrial electron transport chain (ETC). Mitochondrial targeting of the two DBPs isolated from shilajit, and of CoQ10, are considered strategies to augment antioxidant defense and energy-generating elements for restoring normal mitochondrial function. DBPs, as well as their fatty-acyl and amino-acyl conjugates, occur in animal mitochondria and in blood, where they are proposed to act in tandem with CoQ10 in the electron transport chain.

Administration of CoQ10 alone, in mitochondrial deficiency states, may not fully restore normal mitochondrial functions. Mechanisms of oxido-reductase reactions operating in the electron transport chain of animal mitochondria to generate ATP point to a persuasive role of concurrent application of oxygenated DBPs (3,8-(OH)₂-DBP and equivalents) and CoQ10 in animals and humans. To restore the age-related depreciation in the systemic concentration of DBPs in humans, it would be logical to administer DBPs from exogenous sources such as shilajit or ammonites.

The energy-augmenting effects of shilajit were reported to be comparable to those of CoQ10 administered orally to animals as a positive control at 15 mg/kg body weight. DBP, fulvic acid, and their derivatives are described as the principal constituents of shilajit contributing to these effects, and antioxidant activities have been demonstrated using DPPH radical scavenging assay, superoxide anion scavenging assay, ABTS assay, FRAP assay, nitric oxide radical scavenging activity assay, and assay for inhibition of erythrocyte membrane lipid peroxidation.

Relationship with CoQ10

DBPs found in purified shilajit preparations act as electron carriers within the mitochondrial electron transport chain. They help stabilize Coenzyme Q10 (CoQ10) in its active form, allowing for a more efficient transfer of electrons, which reduces "electron leakage" (which causes oxidative stress) and increases the proton gradient needed to generate ATP.

Proposed Additional Mechanisms

In animal research, mitochondrial bioenergetics and the activity of the hypothalamus-pituitary-adrenal (HPA) axis have been evaluated as plausible mechanisms of action for shilajit containing DCPs. In analytical studies, DCP fractions demonstrate superior immunomodulatory and adaptogenic activity compared to isolated fulvic acid.

It is important to note that the precise mechanism by which DCPs specifically (as distinct from the whole shilajit complex or free DBPs) exert biological effects in humans has not been established through direct, isolated human clinical trials. The mechanisms described above derive from in vitro studies, animal models, and inferences from human studies on whole shilajit preparations.

Scientific Evidence by Area of Use

Important evidentiary note: No human clinical trial to date has tested DCPs as an isolated, purified ingredient. All human clinical evidence is for whole purified shilajit preparations that are standardized partly by their DCP content. The strength of evidence for DCPs specifically is therefore indirect and preliminary.

Testosterone and Male Reproductive Hormones

Purified shilajit (an Ayurvedic rasayana) was evaluated in healthy volunteers aged 45–55 years for its effect on testosterone in a randomized, double-blind, placebo-controlled clinical study at a dose of 250 mg twice daily. Treatment for 90 consecutive days significantly (P < 0.05) increased total testosterone, free testosterone, and dehydroepiandrosterone (DHEAS) compared with placebo. Gonadotropic hormone (LH and FSH) levels were well maintained.

This same trial (Pandit et al.) reported that 500 mg/day PrimaVie® Shilajit for 90 days increased baseline testosterone (4.84 ± 1.54 ng/mL), free testosterone (15.36 ± 7.17 pg/mL), and DHEA (145.09 ± 53.17 μg/dL) by 20.45%, 19.14%, and 31.35%, respectively, in healthy adult men. The test material was standardized to contain at least 10% w/w DCPs. This is a single small RCT; replication is required before strong conclusions can be drawn.

Muscular Strength and Connective Tissue

Results from a published study demonstrated that 8 weeks of PrimaVie® shilajit supplementation at 500 mg/day promoted the retention of maximal muscular strength following a fatiguing protocol and decreased baseline hydroxyproline (HYP). PrimaVie® shilajit supplementation at 500 mg/day thus elicited favorable muscle and connective tissue adaptations.

A 2026 open-label, single-arm pilot clinical study in 25 healthy male participants aged 21–55 years, receiving 500 mg/day of TruBlk™ Shilajit Resin for 28 days, showed statistically significant within-group improvements in 1RM leg press strength (+12.94%, p < 0.001), muscle endurance (+12.30%, p < 0.001), grip strength of the dominant hand (+5.73%, p = 0.038), and VO₂ max (+1.36%, p < 0.001). Fatigue Severity Scale scores decreased by 32.40% (p < 0.001), and RPE scores decreased by 23.63% (p < 0.001). CRP levels significantly declined by 25.35% (p = 0.023). This was a pilot study without a placebo control; results require confirmation in a blinded RCT.

Chronic Fatigue — Preclinical Evidence

The effect of processed shilajit standardized to DBPs (0.43% w/w), DCP-chromoproteins (20.45% w/w), and fulvic acids (56.75% w/w) was evaluated in a rat model of chronic fatigue syndrome (CFS). Mitochondrial bioenergetics and the activity of the hypothalamus-pituitary-adrenal axis were evaluated as plausible mechanisms of action. CFS was induced by forcing rats to swim for 15 minutes for 21 consecutive days; the animals were treated with shilajit at 25, 50, and 100 mg/kg for 21 days before exposure to the stress procedure. This is animal (preclinical) evidence only; clinical translation has not been demonstrated.

Body Weight and Metabolic Effects — Preclinical Evidence

Three groups of adult C57/BL6 mice (n=8) were intragastrically supplemented with purified shilajit, 3,8-dihydroxy-dibenzo-alpha-pyrone (3,8-(OH)₂-DBP), or placebo for 12 weeks. Body weight was measured every week, and at the end of week 12 skeletal muscle tissue was harvested for gene profiling. The shilajit preparation used was standardized to contain not less than 50% by weight fulvic acids, at least 10% by weight dibenzo-alpha-pyrone chromoproteins, and at least 0.3% by weight total DBPs. This is animal (preclinical) evidence only.

Inflammatory and Metabolic Biomarkers — Emerging Human Evidence

Niranjan et al. (2016) found that shilajit supplementation at 250 mg twice daily for 12 weeks improved endothelial function and reduced high-sensitivity C-reactive protein (hsCRP) and malondialdehyde (MDA), while increasing nitric oxide (NO) and glutathione (GSH) in patients with type 2 diabetes. These findings are preliminary and drawn from a single study.

Neuroprotective Properties — Preclinical Evidence

Shilajit is a natural phytocomplex known for centuries in Ayurveda for its antioxidant, immunomodulatory, and neuroprotective properties; however, there is little published scientific evidence to support these acclaimed properties. One study assessed neuroprotective effects and amyloid beta-induced cytotoxicity and inflammation of shilajit samples from different geographical origins, examining neuroblastoma cell lines (SH-SY5Y and IMR-32) and cell viability assays, as well as inhibitory effects on proinflammatory cytokines in macrophage cells in vitro and in a murine model. This is in vitro and animal evidence only; no human trials specifically on DCP-standardized shilajit for neuroprotection have been published.

Body Systems Associated with DCPs/Shilajit

• Energy metabolism and mitochondrial function: Primary mechanistic evidence (in vitro, animal models, indirect human evidence through whole shilajit trials).
• Male reproductive endocrinology: One small RCT showing increases in testosterone and DHEAS.
• Musculoskeletal system: Small human studies suggesting retention of strength and reduction of fatigue.
• Inflammation: Emerging human evidence of CRP reduction; mechanistic antioxidant data in vitro.
• Glucose metabolism / diabetes: Ancient practitioners used shilajit to treat various metabolic disorders, including what is now understood as diabetes; modern evidence for this indication in humans is limited.
• Nervous system / neuroprotection: Preclinical evidence only; no confirmed human RCTs.

Forms and Preparations

Shilajit (and by extension DCP-containing preparations) is commercially available as a solid, paste, or extract, and contains minerals such as iron, calcium, magnesium, manganese, and selenium.

Pharmaceutical and supplement formulations described in patent literature include:

• Pharmaceutical, nutritional, skin care, and personal care formulations.
• Capsule and tablet forms containing purified shilajit standardized by DCP and DBP content.
• Resin dissolved in warm water, as used in the 2026 pilot clinical study.

The traditional Ayurvedic purification process known as Shodhana was designed long before chromatography existed, yet it remarkably concentrates DBPs while removing rock debris and soluble toxins.

Dosages Reported in Human Studies

• 250 mg twice daily (500 mg/day): Used in a randomized, double-blind, placebo-controlled clinical study evaluating testosterone levels in healthy male volunteers aged 45–55 years over 90 consecutive days.
• 500 mg/day for 8 weeks: Used in a study that demonstrated retention of maximal muscular strength following fatiguing exercise and decreased serum hydroxyproline.
• 250 mg twice daily (500 mg/day) for 28 days: Used in the 2026 open-label pilot study, dissolved in approximately 200 mL of warm water and taken with meals.
• 25, 50, and 100 mg/kg body weight for 21 days (animal data): Used in a rat model of chronic fatigue syndrome before exposure to the stress procedure.

Safety Considerations

Heavy Metal Contamination

The most consistently documented safety concern for shilajit products (and thus DCP-containing preparations) is heavy metal contamination. Shilajit contains around 65 heavy metals, including toxic metals such as Cu, Al, Pb, As, Cd, and Hg; however, humic substances in shilajit actively detoxify approximately 12 heavy metals. The recommended levels of heavy metals by WHO and FDA in herbal drugs are 0.20–0.30 ppm for Cd, 1 ppm for Hg, 10 ppm for As and Pb, 20 ppm for Cu, and 50 ppm for Zn. The levels of reported metals in shilajit were found to be lower than these permissible limits in most studies, except in a few studies where exceeded levels were reported. Shilajit consumption without knowledge of permissible metal levels is not safe and could pose serious health problems.

In one in vitro and in vivo study, all shilajit samples met the established U.S. Food and Drug Administration limits for adult exposure (130, 20, 75, and 55 μg/day for As, Hg, Pb, and Cd, respectively), at a 500 mg daily dose.

Analytical Testing Requirements

Shilajit preparations used in clinical research are manufactured in GMP facilities using solvent-free aqueous extraction, standardized to ≥60% fulvic acids, confirmed for DBP markers, and tested for heavy metals, microbial load, pesticides, aflatoxins, and polycyclic aromatic hydrocarbons (PAHs) within accepted safety limits.

Regulatory Status and Oversight

Global regulatory authorities continue to intensify scrutiny of heavy metal contamination in supplements. Canadian agencies have issued warnings and may detain unauthorized Ayurvedic imports due to contaminant detection. The European Union applies extensive requirements for shilajit as a novel food or herbal supplement, mandating comprehensive safety assessments.

Unpurified vs. Purified Forms

Research has consistently shown that unpurified or poorly processed shilajit can contain dangerous levels of toxic metals that accumulate in the body over time, potentially causing serious health problems. Despite promising findings in clinical studies, significant gaps preclude a clear understanding of shilajit's role as an ergogenic aid; critically, nearly all prior human trials have investigated purified extracts, not the traditional resin formulation purported to contain the full bioactive spectrum.

Contraindications and Study Exclusion Criteria

In clinical research, participants with metabolic, cardiovascular, renal, or hepatic disorders have been excluded from shilajit trials, as have individuals with recent musculoskeletal injury or surgery, those using anabolic agents, corticosteroids, or anti-inflammatory medications, and those with known allergy to shilajit.

Summary of Evidence Strength

The evidence base for DCPs specifically — as opposed to whole shilajit — is preliminary and indirect. No published human clinical trial has isolated and tested DCPs as a purified compound. The few human RCTs that exist tested whole purified shilajit preparations standardized partly by DCP content, with small sample sizes and, in some cases, industry involvement in study design. Animal and in vitro evidence supports plausible mechanisms involving mitochondrial energy metabolism and antioxidant activity, but these findings require confirmation in well-powered, independently funded human clinical trials. There is little published scientific evidence to directly support the acclaimed properties attributed to shilajit's constituent fractions. Systematic reviews and Cochrane-level evidence for DCPs or shilajit are absent from the current literature.

References

• U.S. Patent Application US20050233942A1 — Oxygenated Dibenzo-Alpha-Pyrone Chromoproteins (USPTO, 2005)
• Canadian Patent Application CA2562829A1 — Oxygenated Dibenzo-Alpha-Pyrone Chromoproteins (CIPO, 2006)
• U.S. Patent US9901596B2 — Regulation of Body Weight Gain by Using Dibenzo-Alpha-Pyrones (USPTO, 2018)
• Pandit S et al. — Clinical evaluation of purified Shilajit on testosterone levels in healthy volunteers. Andrologia, 2016 (PubMed)
• Keller JL et al. — The effects of Shilajit supplementation on fatigue-induced decreases in muscular strength and serum hydroxyproline levels. JISSN, 2019 (PMC)
• Yadav et al. — Safety and Efficacy of TruBlk™ Shilajit Resin Supplementation on Physical Performance and Blood Biomarkers in Healthy Adults: A 28-Day Open-Label Pilot Study. Cureus, 2026 (PMC)
• Surapaneni DK et al. — Shilajit attenuates behavioral symptoms of chronic fatigue syndrome by modulating the hypothalamic-pituitary-adrenal axis and mitochondrial bioenergetics in rats. Journal of Ethnopharmacology, 2012 (ScienceDirect)
• Shilajeet — Overview. ScienceDirect Topics
• Rajput VD et al. — Hazardous or Advantageous: Uncovering the Roles of Heavy Metals and Humic Substances in Shilajit with Emphasis on Heavy Metals Toxicity and Their Detoxification Mechanisms. PubMed, 2024
• Shilajit, a Natural Phytocomplex Acts as a Neuroprotective Agent Against Amyloid Beta-induced Cytotoxicity and Inflammation. Integrative Medicine, 2024
• Bhattacharyya S et al. — Shilajit dibenzo-alpha-pyrones: Mitochondria-targeted antioxidants. Pharmacologyonline, 2009
• U.S. Patent US8894993 — Mitochondria-Targeted Antioxidants (USPTO)
• Carrasco-Gallardo C et al. — Shilajit (Mumie): Current Status of Biochemical, Therapeutic and Clinical Advances. ResearchGate